
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitiv... MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.06 | -5 | 1.2 | 1.39 | 1.07 | 9650888 | 1.20685037 | CS |
4 | -0.11 | -8.8 | 1.25 | 1.39 | 1.07 | 2292301 | 1.20871607 | CS |
12 | -0.16 | -12.3076923077 | 1.3 | 1.53 | 0.83 | 2041108 | 1.13694689 | CS |
26 | -0.1729 | -13.1693198263 | 1.3129 | 1.53 | 0.73 | 1079984 | 1.13649039 | CS |
52 | 0.6269 | 122.178912493 | 0.5131 | 5.01 | 0.5131 | 2292209 | 2.57696138 | CS |
156 | -5.86 | -83.7142857143 | 7 | 7.9799 | 0.51 | 1329435 | 2.51313085 | CS |
260 | -5.86 | -83.7142857143 | 7 | 7.9799 | 0.51 | 1329435 | 2.51313085 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions